In last trading session, Molecular Partners AG ADR (NASDAQ:MOLN) saw 0.26 million shares changing hands with its beta currently measuring 1.13. Company’s recent per share price level of $4.20 trading at $0.12 or 2.92% at ring of the bell on the day assigns it a market valuation of $154.82M. That closing price of MOLN’s stock is at a discount of -202.38% from its 52-week high price of $12.70 and is indicating a premium of 16.43% from its 52-week low price of $3.51. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 34100.0 shares which gives us an average trading volume of 3.89K if we extend that period to 3-months.
For Molecular Partners AG ADR (MOLN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.37 in the current quarter.
Molecular Partners AG ADR (NASDAQ:MOLN) trade information
Upright in the green during last session for gaining 2.92%, in the last five days MOLN remained trading in the green while hitting it’s week-highest on Monday, 04/21/25 when the stock touched $4.20 price level, adding 1.18% to its value on the day. Molecular Partners AG ADR’s shares saw a change of -11.56% in year-to-date performance and have moved 5.77% in past 5-day. Molecular Partners AG ADR (NASDAQ:MOLN) showed a performance of -2.23% in past 30-days. Number of shares sold short was 39149.0 shares which calculate 9.49 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 29 to the stock, which implies a rise of 85.52% to its current value. Analysts have been projecting 29 as a low price target for the stock while placing it at a high target of 29. It follows that stock’s current price would drop -590.48% in reaching the projected high whereas dropping to the targeted low would mean a loss of -590.48% for stock’s current value.
Molecular Partners AG ADR (MOLN) estimates and forecasts
This year revenue growth is estimated to fall -86.59% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.12% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 2.97% while estimates for its earnings growth in next 5 years are of 0.85%.
Molecular Partners AG ADR (NASDAQ:MOLN)’s Major holders
Investors also watch the number of corporate investors in a company very closely, which is 9.72% institutions for Molecular Partners AG ADR that are currently holding shares of the company. BVF INC/IL is the top institutional holder at MOLN for having 0.44 million shares of worth $3.17 million. And as of 2024-06-30, it was holding 1.3485 of the company’s outstanding shares.
The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 0.4 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.217 of outstanding shares, having a total worth of $2.89 million.
